Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 3,060,000 shares, a growth of 9.7% from the August 15th total of 2,790,000 shares. Approximately 7.2% of the company’s shares are short sold. Based on an average trading volume of 237,900 shares, the days-to-cover ratio is presently 12.9 days.
Monte Rosa Therapeutics Price Performance
Shares of GLUE stock traded up $0.03 on Wednesday, reaching $5.95. 141,499 shares of the company were exchanged, compared to its average volume of 194,176. The company has a market cap of $300.55 million, a price-to-earnings ratio of -2.36 and a beta of 1.44. The company has a 50-day moving average of $5.13 and a 200-day moving average of $5.25. Monte Rosa Therapeutics has a one year low of $2.44 and a one year high of $8.84.
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $3.20 million. As a group, sell-side analysts predict that Monte Rosa Therapeutics will post -1.89 EPS for the current year.
Insider Buying and Selling at Monte Rosa Therapeutics
Hedge Funds Weigh In On Monte Rosa Therapeutics
Large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its position in Monte Rosa Therapeutics by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,096,787 shares of the company’s stock valued at $35,933,000 after acquiring an additional 155,880 shares in the last quarter. Acadian Asset Management LLC lifted its position in Monte Rosa Therapeutics by 92.5% in the 1st quarter. Acadian Asset Management LLC now owns 55,548 shares of the company’s stock valued at $390,000 after acquiring an additional 26,687 shares in the last quarter. Vanguard Group Inc. lifted its position in Monte Rosa Therapeutics by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 1,635,829 shares of the company’s stock valued at $11,533,000 after acquiring an additional 47,412 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Monte Rosa Therapeutics in the 2nd quarter valued at about $38,000. Finally, EntryPoint Capital LLC purchased a new stake in Monte Rosa Therapeutics in the 1st quarter valued at about $112,000. Institutional investors own 79.96% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have commented on GLUE shares. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Monte Rosa Therapeutics in a research report on Thursday, September 12th. Piper Sandler reissued an “overweight” rating and set a $16.00 price objective on shares of Monte Rosa Therapeutics in a research report on Friday, June 28th. Finally, Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th.
Check Out Our Latest Report on GLUE
Monte Rosa Therapeutics Company Profile
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
See Also
- Five stocks we like better than Monte Rosa Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- How Much Can You Make in Stocks in One Month?
- Retail Stocks Investing, Explained
- This Is the Top Large-Cap Stock Insiders Are Buying
- Buy P&G Now, Before It Sets A New All-Time High
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.